HEPARIN SODIUM
Total Payments
$136,597
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $89,343 | 1 | 0 |
| 2019 | $47,254 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $136,597 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| THE MATERNAL CLIMB TRIAL: CHLOROPROCAINE TO REDUCE THE IMPACT OF MOTOR BLOCK ON PATIENT RECOVERY AFTER SHORT OBSTETRIC SURGERY | B. Braun Medical Inc. | $89,343 | 0 |
| THE MATERNAL CLIMB TRIAL CHLOROPROCAINE TO REDUCE THE IMPACT OF MOTOR BLOCK ON PATIENT RECOVERY AFTER SHORT OBSTETRIC SURGERY | B. Braun Medical Inc. | $47,254 | 0 |
Top Doctors Receiving Payments for HEPARIN SODIUM
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Portland, OR | $136,597 | 2 |
Ad
Manufacturing Companies
- B. Braun Medical Inc. $136,597
Product Information
- Type Drug
- Total Payments $136,597
- Total Doctors 0
- Transactions 2
About HEPARIN SODIUM
HEPARIN SODIUM is a drug associated with $136,597 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is B. Braun Medical Inc..
Payment data is available from 2019 to 2020. In 2020, $89,343 was paid across 1 transactions to 0 doctors.
The most common payment nature for HEPARIN SODIUM is "Unspecified" ($136,597, 100.0% of total).
HEPARIN SODIUM is associated with 2 research studies, including "THE MATERNAL CLIMB TRIAL: CHLOROPROCAINE TO REDUCE THE IMPACT OF MOTOR BLOCK ON PATIENT RECOVERY AFTER SHORT OBSTETRIC SURGERY" ($89,343).